Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

Koeser L, McCrone P.

Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):171-82. doi: 10.1586/erp.13.14. Review.

PMID:
23570427
2.

The cost effectiveness and budget impact of natalizumab for formulary inclusion.

Bakhshai J, Bleu-Lainé R, Jung M, Lim J, Reyes C, Sun L, Rochester C, Shaya FT.

J Med Econ. 2010 Mar;13(1):63-9. doi: 10.3111/13696990903543424.

PMID:
20028199
3.

A budget impact analysis of natalizumab use in Ireland.

Dee A, Hutchinson M, De La Harpe D.

Ir J Med Sci. 2012 Jun;181(2):199-204. doi: 10.1007/s11845-011-0773-6. Epub 2011 Oct 20.

PMID:
22012552
4.

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.

O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.

J Med Econ. 2011;14(5):617-27. doi: 10.3111/13696998.2011.602444. Epub 2011 Jul 22.

PMID:
21777161
5.
6.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112
7.

Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

Guo S, Pelligra C, Saint-Laurent Thibault C, Hernandez L, Kansal A.

Pharmacoeconomics. 2014 Jun;32(6):559-72. doi: 10.1007/s40273-014-0150-1. Review.

PMID:
24643323
8.

Natalizumab for induction of remission in Crohn's disease.

MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. Review.

PMID:
17253580
9.

Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment.

Olofsson S, Wickström A, Häger Glenngård A, Persson U, Svenningsson A.

BioDrugs. 2011 Oct 1;25(5):299-306. doi: 10.2165/11593770-000000000-00000.

PMID:
21942914
10.

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.

Amato MP.

Expert Opin Pharmacother. 2004 Oct;5(10):2115-26. Review.

PMID:
15461547
11.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

12.

[Natalizumab in multiple sclerosis].

Río-Izquierdo J, Montalban X.

Rev Neurol. 2009 Sep 1-15;49(5):265-9. Review. Spanish.

13.

Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.

[No authors listed]

Drugs R D. 2004;5(2):102-7. Review.

PMID:
15293871
14.

Natalizumab: bench to bedside and beyond.

Rudick R, Polman C, Clifford D, Miller D, Steinman L.

JAMA Neurol. 2013 Feb;70(2):172-82. doi: 10.1001/jamaneurol.2013.598. Review.

PMID:
23128399
15.

Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases.

Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK.

Acta Neurol Scand. 2011 Jun;123(6):430-3. doi: 10.1111/j.1600-0404.2010.01426.x. Epub 2010 Sep 16.

PMID:
21492099
16.

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.

Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG.

J Med Econ. 2012;15(6):1149-58. doi: 10.3111/13696998.2012.707631. Epub 2012 Jul 27.

PMID:
22737996
17.

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.

Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J.

Mult Scler. 2008 Jun;14(5):679-90. doi: 10.1177/1352458507086667.

PMID:
18566030
18.

Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.

Sandmann FG, Franken MG, Steenhoek A, Koopmanschap MA.

Health Policy. 2013 Oct;112(3):285-96. doi: 10.1016/j.healthpol.2013.03.006. Epub 2013 Apr 28.

PMID:
23628483
19.

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Rudick RA.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S18-23. doi: 10.3949/ccjm.78.s2.05.

PMID:
22123928
20.

Treating multiple sclerosis with natalizumab.

Iaffaldano P, Lucchese G, Trojano M.

Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Review.

PMID:
22091593

Supplemental Content

Support Center